Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States.

J Clin Oncol

Anil K. Chaturvedi, Eric A. Engels, Ruth M. Pfeiffer, Nicolas Wentzensen, William F. Anderson, and Philip S. Rosenberg, National Cancer Institute; Sean Altekruse, Surveillance, Epidemiology, and End Results Program, National Cancer Institute, Rockville, MD; Brenda Y. Hernandez and Marc T. Goodman, Cancer Research Center of Hawaii, Honolulu, HI; Weihong Xiao, Esther Kim, Bo Jiang, and Maura L. Gillison, The Ohio State University, Columbus, OH; Maria Sibug-Saber, Wendy Cozen, and Lihua Liu, University of Southern California at Los Angeles, Los Angeles; Richard C. Jordan, University of California and Radiation Therapy Oncology Group Biospecimen Resource, San Francisco, CA; and Charles F. Lynch, University of Iowa, Iowa City, IA.

Published: June 2023

AI Article Synopsis

  • - The study investigates the rising incidence and survival rates of oropharyngeal cancers in the U.S., linking these trends to human papillomavirus (HPV) infection, particularly focusing on data from 1984 to 2004.
  • - Results showed a significant increase in HPV prevalence in oropharyngeal cancers over time, with a jump from 16.3% in the late '80s to 71.7% in the early 2000s, along with longer median survival for HPV-positive patients compared to those who were HPV-negative.
  • - The overall incidence of HPV-positive oropharyngeal cancers surged by 225%, while HPV-negative cases dropped by 50%; predictions suggest HPV

Article Abstract

Purpose: Recent increases in incidence and survival of oropharyngeal cancers in the United States have been attributed to human papillomavirus (HPV) infection, but empirical evidence is lacking.

Patients And Methods: HPV status was determined for all 271 oropharyngeal cancers (1984-2004) collected by the three population-based cancer registries in the Surveillance, Epidemiology, and End Results (SEER) Residual Tissue Repositories Program by using polymerase chain reaction and genotyping (Inno-LiPA), HPV16 viral load, and HPV16 mRNA expression. Trends in HPV prevalence across four calendar periods were estimated by using logistic regression. Observed HPV prevalence was reweighted to all oropharyngeal cancers within the cancer registries to account for nonrandom selection and to calculate incidence trends. Survival of HPV-positive and HPV-negative patients was compared by using Kaplan-Meier and multivariable Cox regression analyses.

Results: HPV prevalence in oropharyngeal cancers significantly increased over calendar time regardless of HPV detection assay ( trend < .05). For example, HPV prevalence by Inno-LiPA increased from 16.3% during 1984 to 1989 to 71.7% during 2000 to 2004. Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 20 months; log-rank < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive ( = .003) but not for HPV-negative patients ( = .18). Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000). If recent incidence trends continue, the annual number of HPV-positive oropharyngeal cancers is expected to surpass the annual number of cervical cancers by the year 2020.

Conclusion: Increases in the population-level incidence and survival of oropharyngeal cancers in the United States since 1984 are caused by HPV infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538911PMC
http://dx.doi.org/10.1200/JCO.22.02625DOI Listing

Publication Analysis

Top Keywords

oropharyngeal cancers
28
hpv prevalence
16
united states
12
hpv-negative patients
12
cancers
9
human papillomavirus
8
oropharyngeal
8
incidence survival
8
survival oropharyngeal
8
cancers united
8

Similar Publications

Objectives: A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate of severe toxic effects. Treatment-related death (TRD) is a crucial topic for physicians involved in the curative treatment of HNC.

View Article and Find Full Text PDF

Objectives: This descriptive epidemiological study aims to investigate trends in head and neck cancer (HNC) within the anatomical divisions of laryngeal, oropharyngeal, and oral cavity cancers over the past two decades.

Design: Retrospective population-based observational study.

Setting: Scotland, a constituent country of the United Kingdom, with a population of 5.

View Article and Find Full Text PDF

Objective: Epidemiological surveys were conducted in Nara Prefecture, Japan, to determine the prevalence of head and neck cancer in the region since 1986.

Methods: This study examined the dynamics of visits to 18 medical institutions treating head and neck cancer in Nara Prefecture from 2000 to 2021.

Results: A total of 8,605 patients were registered, with 4,788 being male and 3,787 female.

View Article and Find Full Text PDF

Prevalence and Risk Factors of Oropharyngeal Dysphagia in Newly Diagnosed Head-and-Neck Cancer Patients.

Cancers (Basel)

December 2024

Department of Otorhinolaryngology, Head and Neck Surgery, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.

Background: Head-and-neck cancer (HNC) can cause oropharyngeal dysphagia (OD). Early identification of OD in newly diagnosed HNC patients is important to better prepare patients for their cancer treatment trajectory. The aim of this study is (1) to assess the prevalence of OD in HNC patients within three weeks before the start of cancer treatment and (2) to investigate which demographic and oncological characteristics may be risk factors associated with the risk of OD at baseline.

View Article and Find Full Text PDF

Human papillomavirus (HPV) is a key factor in gynecological oncology. This narrative review investigates the complex connection between HPV and various gynecological cancers. For a comprehensive exploration, we examined the association between persistent HPV infection and cervical cancer and its global prevalence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!